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Abstract	
	
Over	 the	 last	 decade,	 the	 main	 theme	 underlying	 my	 research	 in	 Health	
Economics	 has	 been	 to	 estimate	 how	 the	 Value	 for	Money	 of	 breakthrough	
pharmaceutical	 innovation	 evolves	 with	 the	 availability	 of	 new	 clinical	
information.		
In	 2008,	 Prof.	 H.	 Zur	 Hausen	 received	 the	 Nobel	 Prize	 for	 discovering	 the	
cancerogenic	role	of	HPV	that	he	initially	discovered	in	1976.	Following	that,	in	
1989,	Prof.	 Ian	 Frazer	discovered	 the	HPV	vaccine	 that	 later	 in	2006	became	
available	globally.	After	the	introduction	of	the	vaccine,	the	clinical	information	
concerning	the	HPV	changed	considerably.	At	the	time	of	its	introduction,	the	
HPV	vaccine	was	mostly	used	for	the	prevention	of	cervical	cancer	in	women.	A	
few	years	later,	the	role	of	HPV	as	causative	agent	of	gender-neutral	cancers	was	
proved,	namely	anal,	oral	and	head	and	neck	cancers.	In	2015,	a	new	version	of	
the	vaccine	was	 introduced,	active	on	a	 larger	number	of	HPV	strains	causing	
malignancies.	
The	 five	 publications	 included	 for	 examination	 describe	 the	 historical	
contribution	of	my	 research	 to	 the	assessment	of	 the	economic	 value	 to	 the	
payor	 (National	 Health	 System)	 of	 the	 HPV	 immunisation	 following	 the	
availability	 of	 new	 clinical	 information.	 The	 setting	 is	 constant:	 the	 Italian	
population	covered	by	the	NHS.	The	analytical	approach	varies	according	to	the	
availability	 of	 new	 inputs	 informing	 the	 economic	 models,	 aimed	 to	
demonstrate	the	match	between	economic	assessment	and	the	availability	of	
new	clinical	evidence	about	the	HPV	immunization.	
First,	an	original	Markov	model	 [1]	demonstrated	that	vaccinating	adolescent	
girls	 against	 HPV	 would	 be	 beneficial	 and	 cost-effective	 as	 a	 public	 health	
programme	in	Italy.	To	provide	inputs	to	the	model	relevant	to	Italy,	both	terms	
of	the	economic	assessment	were	drawn	from	original	NHS	data	that	were	used	
in	 two	 publications.	 Specifically,	 a	 standardized	 time	 trade-off	 (TTO)	
methodology	was	used	[2]	to	quantify	the	utility	loss	in	health	states	affected	by	
HPV-	 induced	 pathologies	 in	 Italy.	 On	 the	 other	 hand,	 an	 innovative	 Bound	
Optimisation	Model	[3]	was	developed	to	determine	whether	the	allocation	of	
resources	was	efficient	for	the	prevention	of	HPV	induced	diseases	ex-ante.	
The	outcomes	of	the	cost-effective	analyses	[1,2,3]	were	included	in	the	pricing	
dossier	leading	to	the	initial	reimbursement	of	HPV	vaccine	in	Italy.	
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Furthermore,	the	BEST	II	study	[4]	evaluated	the	cost-effectiveness	of	universal	
vaccination	 compared	with	 selective	 vaccination	 of	 12-year-old	 girls	 and	 the	
economic	 impact	 of	 immunization	 on	 various	 HPV-induced	 diseases.	 In	 this	
paper,	 a	 dynamic	 Bayesian	Markov	model	 was	 developed	 to	 investigate	 the	
transmission	of	HPV	virus	in	cohorts	of	females	and	males.	As	a	result,	gender-
neutral	 HPV	 vaccination	 was	 found	 to	 be	 a	 cost-effective	 alternative	 when	
compared	with	either	cervical	cancer	screening	or	female-only	vaccination.		
Based	on	this	new	evidence,	the	Italian	Government	was	the	first	among	the	G8	
Countries	to	extend	the	HPV	national	immunisation	programme	to	12-year-	old	
boys	(2017).	
Finally,	a	systematic	review	of	the	extant	literature	[5]	showed	that	the	inclusion	
of	additional	HPV	types	in	the	non-violent	(active	on	nine	strains	of	the	virus)	
vaccine	offers	a	significant	potential	to	expand	protection	against	HPV	infection.	
The	study	was	included	in	the	pricing	dossier	for	the	reimbursement	of	the	9-
valent	 HPV	 vaccine	 as	 a	 replacement	 of	 the	 currently	 available	 quadrivalent	
formulation	
My	main	contribution	to	research	has	been	the	use	of	triangulation	to	augment	
the	internal	validity	of	the	outcomes.	Triangulation	has	benefited	investigators,	
methods	 and	 data	 collection.	 In	 addition	 to	 my	 contributions	 to	 the	
development	of	the	overarching	research	plan,	I	also	directly	contributed	to	the	
research	output	of	each	published	paper	submitted	for	examination.	
My	contributions	reflect	the	expected	research	skills	to	be	demonstrated	upon	
conferment	of	a	Doctoral	Degree:	
- Review	of	the	literature	(Papers	1,	4,	5)	
- Formulation	of	research	question	(Papers	1,	2,	3,	4,	5)	
- Choice	of	methods	(Papers	1,	2,	3,	5)	
- Data	collection	(Papers	1,	3,	5)	
- Data	analysis	(Papers	2,	3,	5)	
- Analysis	of	limitations	of	the	research	(Papers	1,	2,	3,	4,	5)	
- Conclusions	and	recommendations	(Papers	1,	2,	3,	4,	5)	
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Key	notions	
	
HPV	virus:	 Human	papillomavirus	 (HPV)	 is	 the	cause	of	many	sexually	
transmitted	 infections.	 The	 transmission	 of	 HPV	 is	 mostly	
through	skin-to-skin	contact.		Over	100	strains	of	HPV	have	
been	 identified,	 	40	of	which	can	affect	genitals,	mouth	or	
throat.	
HPV	vaccine:	 Human	 papillomavirus	 (HPV)	 vaccines	 prevent	 from	 HPV	
types	 causing	 cervical	 cancer	 as	well	 as	penis,	 anus,	 vulva,	
vagina,	and	oropharynx	cancers.	Available	vaccines	protect	
against	two,	four,	or	nine	types	of	HPV.	
HPV	vaccination:	 Like	 other	 immunizations	 preventing	 viral	 infections,	 HPV	
vaccines	stimulate	an	individual’s	immune	system	to	produce	
antibodies	 and	 develop	 adaptive	 immunity	 that,	 in	 future	
encounters	with	HPV,	bind	to	the	virus	and	prevent	it	from	
infecting	cells.	
Selective	
Vaccination:	 Selective	immunization	of	a	single	gender	or	age	group	(e.g.	
12-year-old	girls)	
Gender-neutral		
(universal)	
vaccination:	 Free	 access	 to	 immunization	 which	 does	 not	 discriminate	
between	genders	
Health	economics:	Health	economics	is	an	economic	discipline	concerned	with	
issues	related	to	efficiency,	effectiveness,	value	and	behavior	
in	 the	production	 and	utilisation	of	 health	 and	healthcare.
	 	
Cost-effectiveness:	The	term	cost-effectiveness	compares	the	relative	costs	and	
outcomes	 (effects)	 of	 different	 courses	 of	 action	 and	 has	
been	 used	 to	 depict	 the	 extent	 to	 which	 interventions	
measure	up	to	what	can	be	considered	to	represent	value	for	
money.	
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Preface		
	
The	 main	 argument	 here	 is	 that	 Value	 for	 Money	 of	 breakthrough	
pharmaceutical	 innovation	 changes	 with	 the	 availability	 of	 new	 clinical	
information.	 Health	 Economic	 evaluations	 should	 closely	 monitor	 those	
changes,	to	capture	the	full	value	of	pharmaceutical	innovation	to	society.	
I	was	 fortunate	enough	 to	be	 involved	since	 the	earliest	 stages	 in	 the	Health	
Economic	 assessment	 of	 one	 of	 the	 most	 innovative	 breakthroughs	 of	 the	
century:	the	vaccine	for	the	prevention	of	HPV	virus	infections.		
After	 the	 introduction	of	 the	 vaccine,	 the	 clinical	 information	 concerning	 the	
HPV	changed	considerably:	
1. At	the	time	of	its	introduction,	the	HPV	vaccine	was	mostly	used	for	the	
prevention	of	cervical	cancer	in	women;	
2. A	few	years	 later,	 the	role	of	HPV	as	causative	agent	of	gender-neutral	
cancers	was	proved,	namely	anal,	oral	and	head	and	neck	cancers;	
3. In	2015,	a	new	version	of	the	vaccine	was	introduced,	active	on	a	larger	
number	of	HPV	strains	causing	malignancies.	
	
The	publications	included	for	review	describe	the	historical	contribution	of	my	
research	to	the	assessment	of	the	economic	value	from	the	perspective	of	the	
payor	 (National	 Health	 System)	 of	 the	 HPV	 immunisation	 following	 the	
availability	 of	 new	 clinical	 information.	 The	 setting	 is	 constant:	 the	 Italian	
population	covered	by	the	NHS.	The	analytical	approach	varies	according	to	the	
availability	of	new	inputs	informing	the	economic	models.	A	brief	description	of	
the	 submitted	 evidence	 is	 reported	 below,	with	 the	 aim	 to	 demonstrate	 the	
match	 between	 economic	 assessment	 and	 the	 availability	 of	 new	 clinical	
evidence	about	the	HPV	immunization.		
1. Selective	immunisation	of	school-aged	girls	for	the	prevention	of	cervical	
cancer.	
HPV	vaccination	in	adolescent	girls	was	demonstrated	to	be	a	beneficial	
programme	for	public	health	in	Italy.	This	was	achieved	using	an	original	
Markov	model	[1]	that	also	showed	as	the	vaccination	was	a	cost-effective	
choice	in	Italy.	To	provide	inputs	to	the	model	relevant	to	Italy,	both	terms	
of	the	economic	assessment	were	drawn	from	original	NHS	data:	
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- A	standardized	time	trade-off	(TTO)	procedure	was	adopted	to	
quantify	 “utility	 loss	 in	 health	 states	 affected	by	HPV-induced	
pathologies	in	Italy”	[2];	
- 	An	 innovative	 Bound	 Optimisation	 Model	 was	 developed	 to	
determine	the	“ex-ante	efficiency	of	resources	allocated	for	the	
prevention	of	HPV	induced	diseases”[3].	
The	outcomes	of	the	cost-effective	analysis	[1,2,3]	were	included	in	the	
pricing	dossier	leading	to	the	initial	reimbursement	of	HPV	vaccine	in	Italy.	
	
2. HPV	 is	 a	 gender-neutral	 killer:	 cost-effectiveness	 of	 vaccinating	 boys	
against	HPV.	
The	BEST	 II	 study	 [4]	evaluated	both	the	cost-effectiveness	of	universal	
vaccination	 compared	 with	 cervical	 cancer	 screening	 and	 selective,	
female-only	 vaccination	 and	 the	 economic	 impact	 of	 immunization	 on	
various	 HPV-induced	 diseases.	 A	 dynamic	 Bayesian	model	 investigated	
the	 transmission	 dynamics	 of	 HPV	 in	 cohorts	 of	 females	 and	 males.	
Gender-neutral	HPV	vaccination	was	demonstrated	to	be	a	cost-effective	
option	when	compared	with	either	cervical	cancer	screening	or	female-
only	vaccination.	
Based	on	this	new	evidence,	the	Italian	Government	was	the	first	among	
the	G8	Countries	to	extend	the	HPV	national	immunisation	programme	to	
12-year-	old	boys	(2017).	
	
3. Cost-effectiveness	of	the	new	version	of	the	HPV	vaccine.	
A	systematic	review	of	the	extant	literature	[5]	showed	that	the	inclusion	
of	 additional	 HPV	 types	 in	 the	 9-valent	 vaccine	 (covering	 against	 nine	
strains	of	 the	virus)	offers	a	 remarkable	potential	 to	expand	protection	
against	HPV	infection.		
The	study	was	 included	in	the	pricing	dossier	for	the	reimbursement	of	
the	 9-valent	 HPV	 vaccine	 as	 a	 replacement	 of	 the	 currently	 available	
quadrivalent	formulation	
	
Common	to	all	Health	Economics	studies,	the	publications	included	for	review	
show	several	Authors:	this	is	due	to	the	different	expertise	required	to	validate	
the	inputs	relevant	to	the	models:	economic,	statistical,	epidemiological,	clinical.	
In	any	project,	though,	I	had	a	leading	role	in	the	health	economic	assessment.	
A	 detailed	 list	 of	 my	 contribution	 to	 each	 publication	 is	 reported	 in	 the	
annotated	summary	of	relevant	publication.		
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Synthesis	
	
Significance		
	
This	 thesis	 aims	 to	 demonstrate	 how	 the	 Value	 for	Money	 of	 breakthrough	
pharmaceutical	 innovation	 changes	 with	 the	 availability	 of	 new	 clinical	
information.	 Health	 Economic	 evaluations	 should	 closely	 monitor	 those	
changes,	to	capture	the	full	value	of	pharmaceutical	innovation	to	society.	
This	 thesis	 provides	 an	 evidence-based	 contribution	 to	 the	 evolutionary	
governance	theory	[1].	From	the	perspective	of	the	National	Health	System,	it	is	
uneasy	to	detect	whether	a	change	constitutes	a	real	innovation.	Changes	take	
place	continuously,	in	adaptation	to	the	environment.	Innovation	could	be	seen	
as	an	important	discontinuity	from	the	past,	which	can	take	place	as	a	sudden	
change,	a	step-wise	change	or	a	gradual	change,	although	these	labels	have	little	
theoretical	 relevance.	What	 it	matters	 is	 that	 the	only	mode	of	operating	 for	
social	systems,	such	as	the	NHS,	is	the	continuous	evaluation	of	new	information	
related	to	the	observed	impact	of	innovation	on	the	society.	The	autopoiesis	of	
social	 system	 is	 the	 continuous	 reassessment	of	previous	 information	on	 the	
basis	of	new	ones.	Innovation,	in	this	account,	can	only	be	an	ex-post	account:	
“a	 retrospective	 observation	 in	 which	 an	 event	 is	 defined	 as	 something	
innovative	or	transformative”	[2].	
In	 healthcare,	 evidence	 generation	 is	 often	 not	 conducive	 to	 assessing	 real-
world	innovations	in	a	timely	way,	particularly	where	there	is	a	focus	on	cost-
effectiveness	[3].	
The	case	of	HPV	vaccination	is	iconic	in	this	respect.	
The	discovery	and	development	of	human	papillomavirus	(HPV)	vaccines,	which	
prevent	 a	 range	 of	 HPV-related	 cancers,	 is	 a	 truly	 impressive	 scientific	
achievement.	In	the	decade	since	approval	of	the	quadrivalent	vaccine	for	the	
prevention	of	HPV	types	6,	11,	16,	and	18,	the	vaccine	has	been	shown	to	be	
highly	effective	[4].		
Recently,	 a	 9-valent	 vaccine	 was	 approved,	 which	 protects	 against	 five	
additional	 oncogenic	 HPV	 types,	 providing	 increased	 protection	 [5].	 The	
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introduction	 of	 this	 improved	 vaccine	 affords	 the	 opportunity	 to	 undo	 an	
unintentional	gender	bias	that	has	harmed	HPV	vaccination	efforts.	
In	origin,	due	 to	 the	association	with	cervical	cancer,	HPV	vaccine	 trials	were	
primarily	 based	 on	 females	 and	 consequently,	 the	 vaccine	 was	 reasonably	
approved	 only	 for	 females	 between	 9	 and	 26	 years	 old.	 However,	 this	
administration	schedule	also	 fit	within	an	existing	cultural	narrative	 that	HPV	
was	 a	 ‘woman's	 problem’.	 The	 identification	 of	 HPV	 with	 females,	 and	 its	
subsequent	impact	on	the	setting	of	primary	prevention	strategies,	was	defined	
as	 the	 "feminization	 of	 HPV".	 The	 process	 of	 ‘feminization’	 occurs	 when	 an	
“issue	 is	 socially	 constructed	 as	 focused	 on	 females,	 which	 can	 impact	 how	
issues	are	perceived	by	the	public	and	addressed	by	the	government	and	other	
organizations”	[6].	
Therefore,	the	feminization	of	HPV	was,	somehow,	the	result	of	an	unintended	
combination	between	the	state	of	science	at	that	time	and	our	long	history	of	
inequality.	The	choice	to	allow	the	vaccine	only	for	females	was	ascribable	to	
science,	politics,	economics,	and	socially	constructed	beliefs	on	gender	roles.	In	
the	forthcoming	transition	from	the	quadrivalent	to	the	9-valent	vaccine	that	
will	 certainly	 involve	 a	 turmoil	 regarding	 guidelines,	 dosage,	 clinical	 practice	
behavior,	 and	 health	 communications,	 new	 strategies	 could	 correct	 gender	
disparities	in	vaccine	delivery.		
HPV	 is	 not	 gender-specific.	 The	 feminization	 of	 HPV	 is	 both	 influenced	 and	
complicated	 by	 its	 sexual	 transmissibility.	 Before	 the	 approval	 of	 the	 HPV	
vaccine,	thanks	to	the	achievements	reached	by	the	Papanicolau	test	screening,	
the	association	of	HPV	with	females	has	contributed	to	a	reduction	in	morbidity	
and	mortality	rates.	Yet,	the	juxtaposition	of	HPV	and	female	cancers	has	limited	
the	debate	on	the	prevention	of	other	HPV-related	cancers,	such	as	anal	and	
oropharyngeal	cancers,	which	also	do	not	take	advantage	of	routine	screenings.	
As	 a	 result	 of	 the	 delayed	 diffusion	 of	 scientific	 evidence	 connecting	males,	
cancers	 and	 HPV,	 vaccine	 recommendations	 for	 males	 were	 postponed	 and	
were	 included	 in	 separate	 guidelines.	 Consequently,	 unsettling	
recommendations	 based	 on	 gender	 and	 age	 continue	 to	 exist	 for	 the	 HPV	
vaccine,	with	a	markedly	lower	uptake	among	males.		
The	 deeper	 concern	 is	 that	 the	 feminization	 of	 HPV	 results	 in	 males	 not	
benefiting	 from	 this	 vaccine.	 In	 fact,	 low	 vaccine	 rates	 among	 females	 (well	
below	the	80-90%	coverage	required	by	the	herd	immunity	to	have	effect),	as	
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well	 as	 heteronormative	 conventions	 (e.g.,	 ignoring	men	who	 have	 sex	with	
men)	 have	 ultimately	 plagued	 the	 hypothesis	 that	 having	 adequate	 HPV	
vaccination	rates	among	females	would	ultimately	protect	males	through	herd	
immunity.	Indeed,	the	introduction	of	the	vaccine	for	females	only,	biased	the	
cost-effectiveness	question	as	 it	 had	not	 asked	 for	 any	other	 vaccine	before.	
That	is,	the	question	was	framed	as,	"is	it	cost-effective	to	add	male	vaccination	
to	 existing	 female	 vaccination?"	 rather	 than,	 "is	 it	 cost-effective	 to	 vaccinate	
both	 males	 and	 females	 compared	 to	 not	 vaccinating	 anyone?"	 The	 cost-
effectiveness	controversy	around	male	vaccination	is,	in	part,	a	result	of	the	lag	
between	 female	 and	male	 licensure.	 Thus,	 the	diffusion	of	 cost-effectiveness	
evaluations	for	males	continues	to	create	an	unequal	approach	to	vaccine	policy.	
The	last	decade	of	my	research	work	has	been	entirely	dedicated	to	fill	the	gap	
between	 evidence	 generation	 and	 assessment	 of	 the	 social	 value	 of	 HPV	
immunisation	 strategies.	 The	aim	was	 to	maximise	 the	access	 to	vaccination,	
hence	 reducing	 inequalities	 between	 genders,	 sexual	 preferences	 and	
behaviors.	
The	 following	paragraph	will	briefly	 review	the	extant	 literature	on	the	social	
value	of	gender-neutral	HPV	vaccination.	The	following	paragraphs	will	discuss	
the	research	approach,	methodological	options	and	contributions	underpinning	
the	body	of	publications	submitted	for	assessment.	
	
Review	 of	 the	 published	 models	 on	 the	 cost-effectiveness	 of	 gender-neutral	 HPV	
vaccination.	
	
The	access	to	new	vaccines	against	HPV,	has	led	policymakers	to	take	decisions	
regarding	 the	most	cost-effective	 immunisation	strategies	 required	 to	 reduce	
the	burden	of	HPV	infections	and	associated	diseases.	The	recognition	that	male	
HPV	 infection	has	a	significant	 impact	on	 the	burden	of	HPV-related	diseases	
justifies	 the	 question	 of	 whether	 males	 should	 be	 or	 not	 included	 in	 the	
vaccination	programme.	
Increasing	 demand	 for	 economic	 and	 epidemiological	 studies	 resulted	 in	 the	
development	 and	 publication	 of	 complex	 statistical	 models	 looking	 at	 the	
efficacy	 and	 cost-effectiveness	 of	 the	 available	 HPV	 vaccines,	 screening	
programmes	and	immunisation	strategies.	However,	from	the	extant	literature	
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emerges	 that	 positions	 on	 gender-neutral	 vaccination	 against	HPV	 (excluding	
the	studies	submitted	for	examination)	have	been	contradictory.		
Two	 studies	 [7,	 8]	 reported	 the	 universal	 vaccination	 against	 HPV	 as	 cost-
effective.	 However,	 as	 pointed	 out	 in	 many	 other	 contributions,	 a	 gender-
neutral	vaccination	schedule	was	also	“possibly	cost-effective”,	“secondary	to	
increasing	 immunisation	 coverage	 of	 women”	 [9,	 10],	 and	 ultimately	 “never	
cost-effective”	according	to	three	studies	[11,	12,	13].		
The	heterogeneity	of	outcomes	observed	 in	the	reviewed	publications	results	
from	the	“high	degree	of	sensitivity	to	boundary	conditions	and	the	choice	of	
inputs”.	Specifically,	some	factors	justified	the	increase	of	the	incremental	cost-
effectiveness	ratio	(ICER)	values	such	as:	“the	higher	vaccine	efficacy,	duration	
of	 protection,	 cross-protection,	 duration	 of	 immunisation,	 and	 observation	
period”.	Conversely,	ICER	values	were	decreasing	when	including	a	“larger	set	
of	HPV-induced	diseases	 (such	as	 recurrent	 respiratory	papillomatosis	 -	RPP),	
lifetime	duration	of	 efficacious	 vaccination	 (no	 subsequent	 ‘booster’	 dose),	 a	
reduced	number	of	doses	needed	to	complete	immunisation	(two	versus	three)	
and	a	lower	unit	price	per	vial	of	the	vaccine”.	Funding	might	also	play	a	role	in	
the	choice	of	the	inputs	to	inform	the	economic	models.	
Therefore,	the	likelihood	of	adding	boys	that	is	shown	by	the	difference	between	
the	observed	ICER	values	and	the	acceptability	threshold	(that	is	usually	set	at	
$50,000	 or	 £30,000),	 may	 depend	 on	 the	 general	 effect	 of	 the	 interaction	
between	the	various	inputs	to	the	model.	As	an	example,	the	highest	ICER	(in	
$2015	values)	observed	among	 the	studies	 included	 in	 the	systematic	 review	
was	 >$200,000.	 This	 value	 was	 driven	 by	 the	 highest	 level	 of	 immunisation	
coverage	observed	 in	 the	 review	 (75%	of	all	 12-26-year-old	women,	a	13-26-
year-old	 women	 catch-up	 cohort	 and	 75%	 of	 all	 12-year-old	 males),	 by	 an	
elevated	(90	to	100%)	adherence	to	a	three-dose	vaccination	schedule,	and	by	
a	relatively	high	vaccine	price	($128	per	vial).	
As	 a	 consequence	 of	 the	 large	 variance	 observed	 in	 the	 use	 of	 different	
economic	inputs	over	the	time,	the	resulted	volatility	implied	in	the	ICER	values	
suggests	 the	 need	 for	 an	 “expiration	 date”	 on	 the	 validity	 of	 the	 normative	
outcomes	 stemming	 from	 cost-effectiveness	 analyses.	 Economic	 and	
demographic	inputs,	however,	are	not	the	only	parameters	that	may	be	affected	
by	significant	changes	over	time.	
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Research	approach		
	
The	 main	 body	 of	 my	 research	 is	 driven	 by	 a	 pragmatic	 approach	 of	 mixed	
methods	 applied	 to	 the	 assessment	 of	 the	 social	 value	 of	 HPV	 vaccination	
strategies.	This	 logic	appeared	best	suited	to	 investigate	the	variety	of	 inputs	
and	 methods	 that	 were	 relevant	 to	 inform	 policy	 decisions	 in	 healthcare,	
allowing	 the	 required	 freedom	 in	 the	 choice	 of	 different	 quantitative	
approaches.	Each	method,	though,	has	its	limitations	and	different	techniques	
can	be	complementary.	
In	 fact,	 the	 way	 of	 analysing	 data,	 depends	 on	 which	 measures	 have	 been	
employed	and	how	the	data	have	been	collected.	Qualitative	data,	however,	can	
be	transformed	into	quantitative	values,	,	by	using	quality	of	life	questionnaires	
to	elicit	utility	values,	for	instance.	
Being	 able	 to	 integrate	 different	 approaches	 has	 the	 advantages	 of	 enabling	
triangulation	[14].	Triangulation	is	a	common	feature	of	mixed	methods	studies	
and	involves,	for	example:	
	
• “the	use	of	a	variety	of	data	sources	(data	triangulation)	
• the	use	of	several	different	researchers	(investigator	triangulation)	
• the	 use	 of	 multiple	 perspectives	 to	 interpret	 the	 results	 (theory	
triangulation)	
• the	use	of	multiple	methods	to	study	a	research	problem	(methodological	
triangulation)”	[15].	
	
Main	research	construct:	modeling	health	economic	outcomes		
	
Health	economic	evaluation	is	a	common	framework	widely	adopted	for	taking	
policy-oriented	 decisions	 about	 whether	 particular	 health	 technologies	
represent	 a	 cost-effective	 use	 of	 healthcare	 resources.	 Typically,	 the	 cost-
effectiveness	of	a	given	set	of	alternative	health	technologies	requires	extensive	
evidence	 that	 is	 not	 available	 from	 a	 single	 source.	 This	 decision-analytic	
framework	 can	 be	 achieved	 through	 the	 use	 of	mathematical	modeling	 that	
allows	the	“full	range	of	relevant	evidence	to	be	synthesised	and	brought	to	bear	
on	the	decision	problem”	[16].	To	develop	a	decision-analytic	model	an	iterative	
process	is	generally	required	in	which	the	developer	has	to	make	some	choices	
to	define	the	inclusion	criteria	and	how	these	phenomena	should	be	related	to	
one	another.	These	choices	take	place	at	every	stage	of	the	model	development.	
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They	include	the	selection	of	the	appropriate	comparators,	the	health	states	and	
sequences	of	events	 that	will	 influence	 the	model’s	 structure,	and	choices	of	
statistical	methods	required	for	deriving	the	model’s	parameters.	 Importantly	
the	absence	of	perfect	 information	for	the	validation	of	a	model	reflects	that	
there	 is	 rarely	 a	 definitive	 means	 through	 which	 determine	 whether	 these	
choices	are	right	or	wrong.	Instead,	choices	in	models	development	are	made	
from	subjective	judgments,	with	the	ultimate	aim	of	developing	a	model	which	
will	be	useful	to	inform	the	decision	maker.	
Based	on	these	theoretical	premises,	the	main	construct	underlying	my	research	
is	the	development	of	conceptual	modeling	[17],	Figure	1.	
	
Figure	 1:	 Schematic	 representation	 of	 Chilcott’s	 development	 of	 conceptual	 modeling	 in	
healthcare	
	
Source:	17.	 Chilcott	JB,	Tappenden	P,	Rawdin	A,	Johnson	M,	Kaltenthaler	E,	Papaioannou	
D	 et	 al.	 Avoiding	 and	 identifying	 errors	 in	 health	 technology	 assessment	 models.	 Health	
Technology	Assessment	2009;	14(25):i-135	
The	 main	 stages	 in	 the	 model	 development	 follow	 both	 a	 sequential	 and	
iterative	flow:	
1.	Understanding	the	decision	problem:	at	this	initial	stage	the	main	activities	
entail	the	immersion	in	research	evidence	to	define	the	research	question.	This	
can	 also	 be	 achieved	 by	 engaging	 with	 clinicians,	 decision-makers	 and	
methodologists,	with	the	objective	of	understanding	what	is	feasible.	
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2.	Conceptual	modelling:	once	 the	gap	has	been	 identified,	 it	 is	necessary	 to	
“translate	the	understanding	of	the	decision	problem	towards	a	mathematical	
or	technical	model-based	solution”	[18].	
3.	Model	implementation:	then,	the	implementation	of	the	model	is	obtained	
through	the	use	of	a	software	platform.	
4.	 Model	 checking:	 this	 is	 required	 to	 avoid	 model	 errors	 and	 includes	 the	
engagement	with	experts,	 the	check	of	 face	validity,	 testing	values,	 structure	
and	logic,	checking	data	sources	etc.	
5.	Engaging	with	decision:	in	conclusion	the	model	and	the	results	obtained	must	
be	made	accessible	by	the	decision-makers	through	an	appropriate	reporting.	
	
Methods	
	
The	five	published	papers	included	in	this	thesis	were	designed	to	fill	voids	in	
current	 research	 into	 the	 social	 value	 of	 HPV	 vaccination	 in	 Italy	 from	 the	
perspective	of	the	Italian	NHS.	They	were	targeted	at	proving	the	main	argument	
of	 my	 research	 that	 the	 Value	 for	 Money	 of	 breakthrough	 pharmaceutical	
innovation	 changes	 with	 the	 availability	 of	 new	 clinical	 information.	 Health	
Economic	evaluations	should	closely	monitor	those	changes,	to	capture	the	full	
value	of	pharmaceutical	innovation	to	society.	
Within	all	 five	papers,	 the	social	 value	of	HPV	 immunisation	was	approached	
from	 diverse	 settings	 (Table	 1).	 The	 aim	 that	 stands	 behind	 the	 use	 of	 this	
methods	is	to	capture	a	holistic	picture	of	‘Value	in	Health’,	with	the	intention	
that	the	adoption	of	different	perspectives	would	reveal	some	elements	that	do	
not	fit	a	previous	understanding,	and	that	divergent	results	would	promote	a	
“deeper,	more	complex	and	less	evident	explanations”	[19,	20].	One	goal	has	
been	to	“choose	methods	that	complement	each	other	and	thus	increase	the	
validity	of	the	findings”	[21,	22].		Not	only	methodological	triangulation,	but	also	
“investigator,	theory	and	data	triangulation”	[23]	has	been	addressed	in	these	
studies.	
	 	
18	
	
	
Table	1:	Methodological	overview	of	the	papers	included	in	the	thesis	
Paper	 Main	research	
question	
Research	
strategy	
Data	collection	
method	
Analysis	
method	
1. Health	 and	
economic	
impact	
associated	with	
a	 quadrivalent	
HPV	 vaccine	 in	
Italy.	
To	determine	
the	health	
impact	of	
introducing	
an	HPV	
vaccination	
alongside	the	
existing	
cervical	cancer	
screening	
programme	in	
Italy.	
Cost-
effectiveness	
analysis:	a	
static	Markov	
model	based	
on	Us	data	was	
adapted	to	the	
Italian	context.	
	
Italian	
epidemiological	
data	from	
published	
literature	were	
used	to	inform	
the	model.	
Then	a	
hierarchical	
approach	was	
used	to	fit	the	
HPV	
prevalence	rate	
Incremental	
Cost	
Effectiveness	
Ratio	(ICER)	
2. Time	 Trade-Off	
Procedure	 for	
Measuring	
Health	 Utilities	
Loss	 With	
Human	
Papillomavirus-
Induced	
Diseases:	 A	
Multicentre,	
Retrospective,	
Observational	
Pilot	 Study	 in	
Italy.	
To	investigate	
the	impact	of	a	
standardized	
time	trade-off	
(TTO)	
procedure	on	
utilities	loss	in	
health	
states	affected	
by	HPV-related	
diseases	in	
Italy.	
Multicentre,	
retrospective,	
observational,	
cross-sectional	
study		
European	
Quality	of	Life–
5	
Dimensions	
(EQ-5D)	
questionnaire	
Spearman	
rank	
correlation	
coefficient		
3. Governance	
of	 preventive	
Health	
Intervention	
and	 On	 time	
Verification	of	
its	 Efficiency:	
the	 GIOVE	
Study.	
To	assess	the	
achievement	of	
allocative	
efficiency	of	
the	budget	
allocated	to	
the	prevention	
of	human	
papillomavirus	
(HPV)-induced	
diseases.	
A	bound	
optimisation	
model	was	
developed	to	
determine	the	
ex-ante	
allocative	
efficiency	of	
resources.	
Real	World	
data	from	the	
Basilicata	
Region:	12	848	
girls	aged	12,	
15,	18	or	25	
years	
Given	the	
budgetary	
constraints,	
the	
vaccination	
coverage	rate	
was	
considered	an	
indicator	of	
the	possible	
benefits.	
4. Analysis	 of	
Universal	
Human	
Papillomavirus	
To	evaluate	
whether	
female-only	
vaccination	or	
A	dynamic	
Bayesian	
Markov	model	
was	designed	
Inputs	from	
published	
literature	and	
All	
parameters	
were	given	
suitable	
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Vaccination	
Using	 a	
Dynamic	
Bayesian	
Methodology:	
The	 BEST	 II	
Study	
universal	
vaccination	is	
the	most	cost-
effective	
intervention	
against	HPV.	
to	investigate	
transmission	
dynamics	in	
cohorts	of	
females	and	
males	in	a	
follow-up	
period	of	
55years.	
clinicians’	
consensus	
probability	
distributions	
5. Human	
papillomavirus	
9-valent	
vaccine	 for	
cancer	
prevention:	 a	
systematic	
review	 of	 the	
available	
evidence.	
To	
systematically	
retrieve	all	
available	
evidence	
on	9vHPV	from	
randomized	
controlled	
trials	
Systematic	
review		
Randomised	
controlled	
clinical	on	
9vHPV	vaccine	
Ten	
publications	
reported	on	
RCTs'	results	
on	9vHPV	and	
were	included	
in	the	
review”.	
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The	 main	 methodological	 choices	 underpinning	 the	 research	 are	 briefly	
described	below.	
Paper	1:		
Markov	static	model		 Markov	models	 are	 frequently	 used	 to	 evaluate	 the	
cost-effectiveness	 of	 a	 one-time	 decision	 (e.g.	
vaccinate	 or	 not	 to	 vaccinate)	 under	 resource	
constraints.	 Models	 with	 embedded	 decisions	 as	
observed	 in	 sequential	 decision	 problems	 cannot	 be	
practically	 solved	 using	 Markov	 models.	 Markov	
decision	processes	(MDPs)	are	analytical	tools	used	for	
sequential	decision	making	under	uncertainty	[24].	
Paper	2:	
Time	Trade-Off	(TTO):	 TTO	 is	widely	 used	 to	 value	 health	 states,	 however,	
there	are	some	limitations.	For	example,	when	people	
are	 asked	 to	 consider	 very	 poor	 states	 of	 health	 –	
persistent	 extreme	 pain,	 for	 example	 –	 they	 may	
dislike	them	so	much	that	they	would	trade	off	all	their	
time	in	full	health.		In	other	words,	they	would	prefer	
to	be	dead.		This	is	called	a	health	“state	worse	than	
death”	(SWD)	[25].	
Paper	3:	
Bound	optimisation:	 Bound	 constrained	 optimizations	 are	 problems	
entailing	the	optimization	of	an	objective	function	that	
is	 subject	 to	 bound	 constraints	 on	 the	 values	 of	 the	
variables.	 Bound	 constrained	 optimization	 problems	
also	arise	when	“the	parameters	that	describe	physical	
quantities	are	constrained	to	be	in	a	given	range”	[26].	
Paper	4:	
Bayesian	models	 Bayesian	 analysis	 refers	 to	 a	 different	 approach	 to	
statistical	inference	in	which	the	purpose	of	collecting	
new	 data	 is	 to	 refine	 the	 estimate	 of	 a	 particular	
quantity	 (often	 a	 probability)	 that	 may	 be	 used	 for	
decision-making.	 This	 contrasts	 with	 traditional	
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‘frequentist’	 statistics	 where	 data	 are	 collected	 to	
reject	or	confirm	a	null	hypothesis	at	a	given	level	of	
statistical	 significance.	 More	 specifically,	 Bayesian	
techniques	are	used	to	“synthesize	information	known	
about	 a	 parameter	 before	 conducting	 a	 study	 with	
new	 data	 from	 the	 study	 to	 estimate	 a	 ‘posterior'	
distribution	for	that	parameter”	[27].	
Cost-effectiveness	 analysis	compares	 the	costs	and	health	effects	of	an	
intervention	 to	 assess	 its	 “value	 for	 money”.	 This	
approach	 is	 used	 to	 assist	 decision-makers	 in	
allocating	limited	healthcare	resources	[28].	
Paper	5:	
Systematic	review	 The	 objective	 of	 systematic	 reviews	 is	 to	 identify,	
critically	 evaluate	 and	 integrate	 the	 findings	 of	
relevant,	high-quality	individual	studies	related	to	one	
or	 more	 research	 questions.	 A	 systematic	 review	 is	
therefore	a	“piece	of	research	in	its	own	right	and,	by	
its	nature,	can	address	much	broader	questions	than	
single	 empirical	 studies	 ever	 can	 (e.g.	 uncovering	
connections	among	many	empirical	findings)”	[29].	
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Outcomes	
	
The	development	of	new	valuation	perspectives	 in	 response	 to	new	 relevant	
inputs	(both	clinical	and	economical)	 lead	over	time	to	a	significant	change	in	
the	social	value	of	HPV	vaccination,	as	illustrated	in	Figure	2.	
This	approach	is	consistent	with	the	main	construct	underpinning	my	research:	
pragmatism	appeared	best	suited	to	research	the	variety	of	inputs	relevant	to	
inform	 policy	 decisions	 in	 Public	 Health,	 such	 as	 the	 optimal	 immunisation	
strategy	to	eradicate	HPV.	By	allowing	the	freedom	to	use	any	of	the	methods,	
techniques	and	procedures	typically	associated	with	quantitative	research,	the	
policy	 recommendation	 moved	 away	 from	 the	 initial	 selective	 strategy	
(vaccinating	 12-year-old	 girls	 only)	 to	 recognising	 the	 social	 value	 of	 gender-
neutral	immunisation	as	soon	as	new	inputs	relevant	to	inform	the	quantitative	
decision	model	(cost-effectiveness	analysis)	became	available.	
Figure	2:	Timeline	of	main	research	outcomes	and	policy	recommendations.	
	
	
The	first	published	paper	dates	to	2008,	which	is	when	the	quadrivalent	vaccine	
was	just	made	available	in	Italy.	Accordingly,	the	objective	of	the	study	was	to	
determine	 the	 health	 impact	 and	 cost-effectiveness	 of	 introducing	 a	
quadrivalent	vaccine	 in	addition	 to	 the	existing	 screening	programme	 for	 the	
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prevention	 of	 cervical	 cancer	 that	was	 the	main	 indication	 approved.	 In	 this	
study,	 through	 the	 adoption	 of	 a	 static	 Markov	 model	 two	 scenarios	 were	
compared:	
•	screen	against	cervical	cancer	(current	context),	
•	HPV	vaccination	with	a	quadrivalent	vaccine	in	association	with	the	existing	
cervical	cancer	screening	programme	provided	in	Italy.	
As	a	result,	the	introduction	of	a	quadrivalent	vaccine	would	provide	substantial	
health	benefits	to	the	Italian	population.	Precisely,	“the	implementation	of	HPV	
vaccination	among	a	cohort	of	girls	aged	12	years	would	avoid	1,432	incremental	
cases	of	cervical	cancer	(−63.3%)	and	513	related	deaths	(−63.4%)	compared	to	
screening	programme	only”.	This	was	obtained	assuming	a	coverage	rate	of	80%	
and	lifetime	duration	of	protection	as	well	as	discount	rates	of	1.5%	and	3%	for	
health	 benefits	 and	 costs	 respectively.	 Furthermore,	 this	 new	 preventive	
strategy	was	reported	to	be	a	“cost-effective	public	health	programme,	as	the	
cost	 per	 additional	 QALY	 gained	 reached	 €9,569,	 which	 is	 considered	 as	 an	
acceptable	threshold”	[30].	
This	 relatively	 simple	 model	 had	 iconic	 importance	 in	 the	 history	 of	 HPV	
vaccinations.	 Published	 almost	 simultaneously	 with	 this	 study,	 a	 cost-
effectiveness	 analysis	 conducted	 by	 Public	 Health	 England	 made	 the	 same	
recommendations	 for	 the	 HPV	 vaccination	 in	 England	 [31].	 The	 cost-
effectiveness	outcomes	have	been	confirmed	by	hundreds	of	studies	published	
in	the	extant	literature,	employing	a	variety	of	sophisticated	methodologies.	The	
selective	 vaccination	 of	 12-year-old	 girls	 rapidly	 became	 the	 preferred	 HPV	
immunisation	strategy	in	Europe	and	most	Countries	with	a	public	NHS.	
In	the	following	years,	Papers	2	and	3	focused	on	methodological	issues	related	
to	the	valuation	of	all	the	HPV-induced	malignancies,	regardless	of	the	gender.	
Paper	2	was	a	pilot	study,	aimed	to	investigate	the	“feasibility	of	a	standardized	
time	trade-off	(TTO)	procedure	to	quantify	utility	loss	in	health	states	affected	
by	HPV-induced	pathologies	in	Italy”.	A	TTO	standardized	procedure	is	expected	
to	be	useful	to	assess	utilities	in	patients	affected	by	HPV-induced	diseases.	
Paper	3	was	concerned	with	another	critical	aspect	of	cost-effectiveness	analysis	
of	vaccination:	the	optimal	coverage	rate.	The	vaccination	coverage	rate	was	the	
indicator	of	the	best	possible	benefit,	given	the	budgetary	constraints.		
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At	a	market-based	price	per	vial	of	the	vaccine,	the	optimal	rate	of	coverage	was	
in	favour	of	the	multiple	cohort	strategy	of	vaccination	against	HPV.		
This	 observation	 had	 an	 extraordinary	 impact	 on	 the	 development	 of	 cost-
effectiveness	of	HPV	vaccination:	if,	give	a	vaccine	price,	the	optimal	coverage	is	
a	multi-cohort	strategy,	what	would	be	the	economic	impact	to	add	boys	to	the	
vaccination	of	girls?	
Paper	4	provided	an	answer	to	this	novel	research	question.	The	sophisticated	
dynamic	Bayesian	model	suggested	for	the	first	time	that	universal	vaccination	
targeting	the	same	age	group	(12years)	was	an	extremely	cost-effective	strategy	
in	comparison	to	screening-only	or	to	a	single	cohort	of	females.	The	following	
four	innovative	aspects	determined	the	outcomes	of	the	study:	
1.	The	dynamic	force	of	infection,	including	sexual	mating	between	females	and	
males,	 thus	 automatically	 considering	 changes	 in	 mixing	 patterns	 and	
population	prevalence	over	time.		
2.	The	assumption	of	 lifelong	 immunity	 following	 initial	HPV	vaccination	with	
three	doses,	without	the	necessity	of	a	booster	application;		
3.	The	considerably	low	unit	cost	of	vaccination	compared	with	the	official	list	
price	of	the	vaccine	in	the	Italian	market;		
and,	most	important,		
4.	The	inclusion	of	a	high	variety	of	HPV-induced	diseases	compared	with	other	
health-economic	evaluations	that	account	only	for	cervical	cancer.	
The	 last	 observation	 served	 as	 the	 foundation	 for	 Paper	 5,	 aimed	 to	
“systematically	retrieve,	qualitatively	and	quantitatively	pool,	as	well	as	critically	
appraise	 all	 available	 evidence	 on	 9vHPV	 from	 randomized	 controlled	 trials	
(RCTs)”.	In	this	paper,	we	conducted	a	systematic	review	of	the	extant	literature	
on	9vHPV	efficacy,	immunogenicity	and	safety,	as	well	as	a	systematic	search	of	
registered,	completed,	and	ongoing	RCTs.	In	this	work	we	followed	the	review	
method	 named	 PRISMA	 	 (Prepared	 Items	 for	 Systematic	 Reviews	 and	Meta-
Analysis)	and	the	related	guidelines	[22].	
The	 conclusions	 of	 the	 systematic	 review	 of	 the	 extant	 clinical	 literature	
highlighted	as	the	inclusion	of	additional	HPV	types	in	the	vaccine	offered	great	
potential	to	expand	protection	against	HPV	infection	and	the	associated	burden	
of	diseases.	However,	the	9vHPV	impact	in	reducing	the	global	burden	of	HPV-
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related	cancer	was	depending	on	the	vaccine	uptake	and	coverage,	as	well	as	
the	availability,	and	–	finally	–	its	affordability	from	the	perspective	of	the	payer.	
The	conclusions	set	the	stage	for	a	new	wave	of	cost-effectiveness	analysis	of	
the	new	generation	of	9-valent	vaccine,	aiming	to	assess	the	social	value	of	this	
innovative	approach	to	HPV	vaccination	strategy.	
The	 outcomes	 of	 the	 submitted	 body	 of	 research	 established	 the	 cost-
effectiveness	 of	 the	 selective	 HPV	 vaccination,	 posed	 new,	 fundamental	
question	on	how	the	value	for	money	was	assessed,	recognised	the	necessity	of	
a	 gender-neutral,	 universal	 vaccination	 and	 clarified	 the	 premises	 for	 the	
adoption	of	a	new	generation	of	vaccines,	active	on	a	broader	spectrum	of	HPV	
oncogenic	strains.	
By	integrating	new	information	into	progressively	more	sophisticated	models,	
the	 research	 questions	 anticipated	 the	 development	 of	 new	 and	more	 cost-
effective	HPV	immunisation	strategies,	providing	a	substantive	contribution	to	
the	field	of	valuation	of	the	social	value	of	pharmaceutical	innovation.		
	
Limitations	of	research	outputs	
	
The	cost-effectiveness	models	(Paper	1	and	4)	submitted	for	examination	do	not	
address	 the	 issue	of	equality	 in	Public	Health	raised	by	a	selective	 (girls-only)	
vaccination	strategy.	The	principle	of	equity	and	equal	access	to	healthcare	to	
maximize	a	population’s	health	is	a	cornerstone	for	all	health	systems.	Therefore	
the	 universal	 vaccination	 would	 give	 men	 and	 women	 the	 same	 rights	 to	
protection	and	would:	
- protect	 females	and	males	against	many	HPV-related	diseases	
such	 as	 cervical,	 vulvar,	 vaginal	 and	 anal	 (pre)	 cancers,	 and	
genital	warts	and	significantly	reduce	the	remaining	burden	 in	
both	genders;	
- improve	the	control	of	HPV	vaccine	types	circulation	and	related	
diseases	and	this	would	potentially	lead	the	“quasi-elimination	
of	vaccine”.		
- lead	HPV	vaccination	to	become	a	standard	vaccination	schedule	
in	pre-adolescents;	
- reduce	gender	and	social	health	inequalities	by	protecting	men	
against	 unvaccinated	 female	 or	 male	 partners	 (increased	 risk	
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with	 population	 movements)	 and	 protecting	 the	 most	
vulnerable	people	through	the	prevention	of	genital	warts.	
	
A	 second	 limitation	 is	 related	 to	 the	 choice	 of	 cost	 inputs	 that	was	made	 to	
inform	the	models.	This	was	 limited	by	the	perspective	of	valuation	(the	NHS	
system)	and	by	choice	of	including	direct	costs	only.	The	full	economic	benefits	
of	HPV	vaccination	are	difficult	to	be	quantified	 in	monetary	terms,	unless	all	
indirect	costs	are	included	in	the	analysis	(e.g.:	decrease	of	the	burden	for	the	
caregiver,	 psychosocial	 impact,	 impact	 on	 fertility,	 productivity	 loss).	
Consequently,	based	on	existing	guidelines,		the	cost-effectiveness	is	unlikely	to	
be	the	most	relevant	measure	for	the	assessment	of	the	broad	social	value	of	
HPV	gender-neutral	vaccination.	
	
Research	quality	and	relevance	
	
Impact	factor	
	
The	 impact	 factor	 (IF)	 is	 a	measure	of	 the	number	of	 citations	 received	by	 a	
paper	 published	 in	 a	 particular	 year.	 It	 is	 used	 to	 measure	 the	 academic	
relevance	of	a	journal	by	calculating	the	times	the	articles	are	cited.	
It	is	commonly	adopted	as	an	indirect	quality	of	the	papers	published,	since	the	
acceptance	for	publication	process	is	generally	more	difficult	and	selective	the	
higher	the	IF	of	the	Journal	[32].	
The	IF	of	the	five	published	papers	submitted	was	included	between	2.2	<>3.8.	
• Paper	1:	IMPACT	FACTOR:	3.774	
• Paper	2:	IMPACT	FACTOR:	2.731	
• Paper	3:	IMPACT	FACTOR:	2.271	
• Paper	4:	IMPACT	FACTOR:	3.824	
• Paper	5:	IMPACT	FACTOR:	2.515	
	
																																																																																																																																							
Citations	
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Citation	analysis	is	a	second	approach	that	is	adopted	to	measure	the	relative	
impact	 of	 an	 author,	 an	 article	 or	 a	 publication.	 It	 consists	 of	 “counting	 the	
number	of	 times	 an	 author,	 article,	 or	 a	 publication	has	 been	 cited	by	other	
published	works”	[33].	
The	five	papers	submitted	for	examination	have	been	cited	70	times	in	similar	
publications	(source:	ResearchGate	and	PubMed).	
• Paper	1:	CITATIONS:	51																																																													
• Paper	2:	CITATIONS:	5	
• Paper	3:	CITATIONS:	2	
• Paper	4:	CITATIONS:	7	
• Paper	5:	CITATION:	5	
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Personal	contribution	to	research	
	
1. Triangulation	
	
In	the	body	of	research	submitted	for	examination,	I	explored	some	of	the	key	
considerations	of	data	analysis	and	interpretation	for	a	complex	evaluation.	The	
synthesis	 among	 multiple	 and	 complementary	 sources	 is	 vital	 to	 produce	
credible	 evidence	 for	 policy	 recommendations	 in	 the	 healthcare	 sector.	
Therefore,	triangulation	refers	to	the	use	of	multiple	sources	of	qualitative	and	
quantitative	 information,	 data	 collection	 and	 analysis	 methods	 for	 obtaining	
valuable	and	complex	findings	or	conclusions.	The	adoption	of	triangulation	can	
strengthen	the	quality	and	credibility	of	the	evidentiary	support	for	findings	and	
recommendations,	 especially	 in	 the	 complex	 field	 of	 analysis	 such	 as	 the	
healthcare	 where	 any	 single	 data	 source	 will	 have	 inherent	 limitations.	
Triangulation	has	benefited	investigators,	methods	and	data	collection.		
	
1.1	Investigator	triangulation	
	
My	 contribution	 to	 the	 triangulation	 of	 expertise	was	 based	 on	my	 personal	
experience	in	the	field	of	valuation,	with	specific	reference	to	the	assessment	of	
the	social	value	of	HPV	immunisation	strategies,	
My	academic	 leadership	and	experience	 in	the	economics	of	HPV	vaccination	
can	be	comparatively	assessed	by	ranking	the	Authors	of	similar	publications	in	
bibliometric	databases.	My	name	(10	papers)	is	listed	among	the	Top	10	most	
published	 Authors	 of	 HPV	 studies	 at	 a	 global	 level	 (source:	Web	 of	 Science,	
2018).		
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Triangulation	has	benefited	from	multidisciplinary	teams	of	investigators.	In	the	
design	and	implementation	of	the	HPV	projects,	I	had	the	opportunity	to	lead	
and	coordinate	the	research	effort	of	a	variety	of	academic	specialisms,	aiming	
to	add	different	perspectives	to	the	definition	of	the	research	question	and	the	
development	 of	 quantitative	models	 representative	 of	 the	 Italian	 healthcare	
setting.	This	approach	 justifies	 the	number	of	Authors	acknowledged	 in	each	
published	 paper	 submitted.	 As	 project	 leader,	 my	 first	 contribution	 was	 to	
identify,	 recruit	and	facilitate	the	work	of	 leading	experts.	Although	complex,	
multi-location	 teams	 are	 relatively	 difficult	 to	 manage,	 it	 was	 imperative	 to	
acquire	the	highest	number	of	inputs	possible	to	inform	the	models.	Most	of	the	
relevant	perspectives	have	been	included	in	the	analysis	from	leading:		
-	Epidemiologists;	
-	Clinicians;	
-	Public	Health	executive;	
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-	Payors	(Italian	NHS);	
-Health-economic	specialists;	
-	Bayesian	modelers;	
-	Statisticians.	
	
1.2	Method	triangulation	
	
Methodological	triangulation	involves	the	use	of	more	than	one	kind	of	method	
to	address	the	same	research	question.	Benefits	were	found	in	the	confirmation	
of	 findings	and	an	 increased	validity	 such	as	 the	better	understanding	of	 the	
research	outcomes.	Although	many	researchers	have	adopted	this	technique,	
few	examples	have	been	published	[34].		
The	five	published	papers	submitted	for	examination	provide	a	unique	case	for	
method	 triangulation.	 I	 directly	 contributed	 to	 the	 methodological	 choices	
underpinning	all	five	submitted	papers,	following	a	clear	trajectory	leading	from	
the	 first	 static	 model	 (Paper	 1)	 to	 a	 more	 comprehensive	 Bayesian	 cost-
effectiveness	analysis	(Paper	4)	and	future	developments	in	the	estimate	of	the	
social	value	of	gender-neutral	HPV	vaccination	(Paper	5).	
Paper	1	represents	the	starting	point.	In	this	work	we	adopted	a	basic	Markov	
static	model	to	“estimate	the	incidences	of	detected	precancerous	lesions	and	
cervical	cancer”.	Moreover	 the	model	assessed	the	“cervical	cancer	mortality	
rate,	 lifetime	risks	of	precancerous	 lesions	and	cervical	cancer,	deaths	due	to	
cervical	 cancer,	 remaining	 life	 expectancy	 and	 quality-adjusted	 life	 years	
(QALYs)”.	 Using	 this	 approach	 the	 total	 direct	 medical	 costs	 related	 to	 the	
cervical	 cancer	 screening,	 the	 HPV	 vaccination	 programme	 and	 the	
management	of	the	HPV-related	diseases	were	calculated.	Finally,	we	divided	
the	incremental	costs	by	the	incremental	health	outcomes	(number	of	life-year	
gained	(LYG)	or	QALY	gained)	to	obtain	the	incremental	cost-effectiveness	ratios	
(ICERs).	
Paper	 2	 addressed	 a	 fundamental	methodological	 issue	 of	 cost-effectiveness	
analysis,	the	validity	of	the	method	used	to	elicit	patient	utilities.	This	economic	
parameter	 is	 instrumental	 to	 the	 correct	 calculation	 of	 the	 QALY,	 the	
denominator	in	the	cost-effectiveness	ration	(ICER).		
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This	“multicentre,	observational,	retrospective,	cross-sectional	pilot	study”	was	
part	of	a	larger	research	project	comprising	four	studies.	It	was	designed	to	elicit	
health	state	preferences	(utilities)	 in	a	cohort	of	patients	with	a	histologically	
confirmed	 diagnosis	 of	 CIN2-3.	 Among	 HPV-related	 diseases	 (e.g.,	 invasive	
cervical	cancer),	it	was	expected	that	such	lesions	would	have	been	perceived	
with	wide	variability	in	affecting	the	patients'	quality	of	life.	
Paper	3	posed	the	question	of	the	optimal	vaccination	coverage	given	budgetary	
constraints.	The	access	to	publicly	funded	vaccination	is	indeed	another	critical	
input	that	highly	influences	the	outcomes	of	cost-effectiveness	analysis	of	HPV	
immunisation	strategies.	A	bound	optimisation	model	was	then	used	due	to	the	
several	ex-ante	constraints	that	may	affect	the	allocation	of	resources	among	
healthcare	 programmes.	 This,	 allows	 decision	 makers	 to	 maximise	 the	 total	
expected	benefits	for	a	given	budget.	
In	paper	4,	the	methodological	learning	acquired	in	the	implementation	of	our	
previous	research	was	applied	to	the	modelling	of	gender-neutral	vaccination	
policy	in	Italy	by	using	a	dynamic	Bayesian	model	of	the	cost-effectiveness.	By	
adopting	 this	 dynamic	 model,	 we	 accounted	 for	 interactions	 between	
individuals	of	different	sex	in	the	definition	of	the	transition	probabilities	from	
“Exposure”	to	“Infection.”	As	such,	the	HPV	transmission	was	estimated	for	the	
first	time	using	the	dynamic	force	of	infection,	which	is	defined	as	a	“function	of	
HPV	 transmission	 probabilities,	 partner	 acquisition	 rates,	 and	 population	
prevalence”.	 To	 do	 so,	 all	 parameters	 were	 given	 suitable	 probability	
distributions,	to	reflect	the	state	of	science.	However,	as	a	common	feature	of	
pathogenesis	 in	 human	 medicine,	 most	 parameters	 were	 subject	 to	 a	
considerable	 amount	of	 uncertainty	 that	was	propagated	 through	 the	model	
using	Markov	chain	Monte-Carlo	estimation.	
The	uncertainty	observed	in	paper	4	in	the	distribution	of	clinical	parameters	led	
to	the	need	for	the	reassessment	of	all	the	randomised	clinical	trials.	This	was	
the	aim	of	the	systematic	review	of	the	published	clinical	literature	adopted	as	
the	main	method	for	Paper	5.	A	systematic	review	of	the	extant	literature	was	
conducted	 on	 the	 efficacy,	 immunogenicity,	 and	 safety	 of	 the	 new	 9-valent	
vaccine	against	HPV	 (HPV9),	 as	well	 as	a	 systematic	 search	of	 the	 registered,	
completed,	 active,	 and/or	 ongoing	 clinical	 trials	 (RCTs)	 on	 HPV9.	 The	
methodological	rigour	of	systematic	review	of	the	literature	allowed	to	reduce	
the	heterogeneity	of	the	outcomes,	leading	to	the	collection	of	a	robust	set	of	
inputs,	 including	 efficacy,	 immunogenicity,	 and	 safety	 outcomes,	 which	 will	
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inform	 the	 next	 generation	 of	 cost-effectiveness	 studies	 of	 gender-neutral	
vaccination	 strategies	 aimed	 to	 eradicate	 the	 HPV	 threat	 and	 to	 cancel	 the	
economic	burden	of	diseases	imposed	on	society	by	HPV-induced	malignancies.	
	
1.3	Data	Triangulation		
	
The	triangulation	of	data	occurs	when	multiple	theories,	materials	or	methods	
are	used.	Data	triangulation	validates	data	increases	the	internal	credibility	and	
validity	of	research	outputs.	
Although	data	analysed	were	referring	to	one	setting	(the	Italian	population	and	
healthcare	 system),	 the	 five	 papers	 submitted	 for	 examination	 followed	 an	
unprecedented	variety	of	data	collection	approaches.	
In	Paper	1,	available	Italian	epidemiological	data	were	used	to	inform	the	model.	
Then,	the	model	was	empirically	calibrated	hierarchically	to	fit	HPV	prevalence	
rate	as	well	as	age-specific	incidence	and	mortality	rates	of	cervical	cancer,	as	it	
was	observed	among	the	Italian	screened	population.	However,	the	underlying	
natural	history	of	cervical	cancer	was	assumed	to	be	fundamentally	the	same	
across	 countries.	 In	 fact,	 it	 is	well	 acknowledged	 that	“the	patterns	of	 sexual	
behavior	and	the	age	of	sexual	debut	may	vary”	[35].	To	take	into	account	this	
variation,	 the	 incidence	 rates	 of	 HPV	 infection	 were	 adjusted	 to	 the	 Italian	
epidemiological	published	evidence.		
In	paper	2,	three	clinical	research	centres,	located	in	north,	centre	and	south	of	
Italy,	were	involved	in	the	study	to	provide	primary	data.	The	following	criteria	
were	used	to	identify	the	eligible	patients:	“age	between	18	and	65	years	at	the	
time	 of	 diagnosis;	 a	 histologically	 confirmed	 diagnosis	 of	 CIN2-3;	 a	 recorded	
surgical	 procedure	 of	 hospital	 conisation;	 and	 time	 from	 conisation	 to	
administration	of	questionnaires	78	weeks	(to	avoid	the	potential	impairment	
effect	 of	 recollection	 that	 might	 be	 associated	 with	 a	 stressor	 event)”.	 We	
excluded	 patients	 who	 did	 not	 fully	 complete	 the	 questionnaires	 used	 to	
measure	utilities	and	quality	of	life	and	those	with	an	incomplete	clinical	record.	
The	secondary	data	used	to	inform	the	bound	optimization	model	developed	in	
Paper	 3	 were	 also	 provided	 by	 participating	 Italian	 Healthcare	 trusts.	
Specifically,	 five	 Local	 Healthcare	 Authorities	 in	 the	 Basilicata	 Region	 were	
involved	and	data	on	rates	of	screening	and	vaccination,	allocation	of	budgets	
and	costs	(including	the	total	spent	on	prevention)	were	retrieved	on	a	real	base.	
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The	regional	demographic	archive	provided	 information	on	“subjects’	date	of	
birth,	sex	and	healthcare	identification	number,	whereas	data	on	the	course	of	
vaccination	 (including	 the	 patients’	 names	 and	 healthcare	 identification	
numbers,	together	with	dates	of	issue,	brand	names	and	batch	numbers	of	the	
vaccine)	were	obtained	from	the	regional	vaccination	register”.	All	personal	data	
were	replaced	with	a	univocal	numerical	code	to	ensure	that	both	information	
was	anonymous	at	the	source.	
In	 Paper	 4,	 we	 considered	 the	 proportion	 of	 infected	 individuals	 in	 the	
population	available	for	mating	at	a	given	time	and	under	the	three	alternative	
interventions.	This	was	made	to	estimate	the	HPV	population	dynamically.	The	
force	of	infection	was	then	computed	as	the	product	of	these	three	terms	and	
resulted	in	rates	that	were	rescaled	into	probabilities.	
Lastly,	the	systematic	review	of	the	literature	reported	in	Paper	5	was	conducted	
followed	 the	 systematic	 approach	 named	 “PRISMA”	 (Prepared	 Items	 for	
Systematic	 Reviews	 and	 Meta-Analysis)	 guidelines.	 In	 this	 paper,	 published	
studies	were	retrieved	from	the	electronic	databases	Medline,	Embase	and	the	
Cochrane	 Library.	 The	 database	 search	 strategies	 were	 built	 around	 9vHPV-
related	 free-text	 keywords.	 Besides,	 further	 studies	 were	 identified	 and	
downloaded	 from	 reference	 listing	 of	 relevant	 articles	 and	 consultation	with	
experts	in	the	field.	Registered	clinical	trials	were	identified	from	clinical	trials’	
registries	 and	 platforms	 such	 as	 the	WHO	 ICTRP	 (International	 Clinical	 Trials	
Registry	Platform),	the	ClinicalTrials.gov	registry,	the	Cochrane	Central	Register	
of	Controlled	Trials	and	the	EU	Clinical	Trial	Register.	
	
2. Personal	contribution	to	research	output	
	
In	addition	to	my	contributions	to	the	development	of	the	overarching	research	
plan,	I	also	directly	contributed	to	the	research	outputs	of	each	published	paper	
submitted	for	examination.	
My	 contributions	 to	 outputs	 reflect	 the	 expected	 research	 skills	 to	 be	
demonstrated	upon	conferment	of	a	Doctoral	Degree:	
- Review	of	the	literature	(Papers	1,	4,	5)	
- Formulation	of	research	question	(Papers	1,	2,	3,	4,	5)	
- Choice	of	methods	(Papers	1,	2,	3,	5)	
- Data	collection	(Papers	1,	3,	5)	
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- Data	analysis	(Papers	2,	3,	5)	
- Analysis	of	limitations	of	the	research	(Papers	1,	2,	3,	4,	5)	
- Conclusions	and	recommendations	(Papers	1,	2,	3,	4,	5)	
	
My	 contribution	 to	 the	 outputs	 of	 each	 published	 paper	 submitted	 for	
examination	is	summarised	below	in	a	schematic	form.	
1)	Personal	contributions	Paper	1:	
1. Coordination	of	the	scientific	project;	
2. Literature	review;	
3. Research	question;	
4. Design	of	the	economic	model;	
5. Data	collection	of	the	inputs	relevant	to	inform	the	model	
6. Draft	of	the	conclusions;	
7. Analysis	of	limitations;	
8. Contribution	to	the	writing	of	the	paper.		
	
2)	Personal	contributions	Paper	2:	
1. Coordination	of	the	scientific	project;	
2. Research	question;	
3. Design	of	the	economic	model;	
4. Choice	of	the	questionnaire	used	to	collect	data;		
5. Preliminary	analysis	of	collected	data;	
6. Analysis	of	limitations;	
7. Contribution	to	the	writing	of	the	paper.		
	
3)	Personal	contributions	Paper	3:	
1. Coordination	of	the	scientific	project;	
2. Research	question;	
3. Design	of	the	economic	model;	
4. Data	collection	and	verification	with	participating	local	Councils	(ASLs);		
5. Data	analysis;	
6. Draft	of	the	conclusions	(political	economics);	
7. Analysis	of	limitations;	
8. Contribution	to	the	writing	of	the	paper.		
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4)	Personal	contributions	Paper	4:	
1. Coordination	of	the	scientific	project;	
2. Literature	review;	
3. Research	question;	
4. Contribution	to	the	design	of	the	cost-effectiveness	model;		
5. Draft	of	the	conclusions;	
6. Analysis	of	limitations;	
7. Contribution	to	the	writing	of	the	paper.		
	
5)	Personal	contributions	Paper	5:		
Being	the	only	health	economist	involved	in	the	project,	I	conducted	all	stages	
of	research:	
1. Coordination	of	the	scientific	project;	
2. Literature	review;	
3. Research	question;	
4. Data	collection	from	the	extant	 literature	of	all	 inputs	 informing	the	
review;	
5. Data	analysis;	
6. Analysis	of	limitations;	
7. Conclusions;	
8. Contribution	to	the	writing	of	the	paper.		
	
3. Research	impact	
	
The	BEST	II	cost-effectiveness	study	(Paper	4)	extended	the	previously	published	
model	Paper	1),	 including	population	dynamics	 in	an	open	model	structure,	a	
range	of	HPV-induced	diseases,	and	the	dynamical	effects	of	sexual	mixing	to	
account	 for	 herd	 immunity.	 The	 study	 concluded	 that	 universal	 vaccination	
targeting	 the	 12-year	 age	 group	 is	 extremely	 cost	 effective	 in	 comparison	 to	
female-only	vaccination.	The	cost	per	QALY	gained	was	calculated	as	€11,600,	
well	below	the	value	of	€30,000	that	is	usually	considered	to	be	the	threshold	of	
good	value	for	money	in	healthcare	policy.	
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Based	on	the	outcomes	of	the	BESTII	study,	 in	January	2017	the	Italian	Prime	
Minister	Paolo	Gentiloni	signed	a	new	Levels	of	Care	agreement	for	the	Italian	
health	 service	 that	made	 Italy	 the	 first	 EU	 country	 and	G8	nation	 to	adopt	a	
nationwide	gender-neutral	HPV	vaccination	programme.		
The	following	month,	the	National	Vaccination	Plan	was	published	in	full	by	the	
Italian	Minister	of	Health.	This	vaccination	plan	cites	the	BEST	study	as	evidence	
of	the	cost-effectiveness	of	vaccinating	boys.	
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Abstracts	of	the	published	papers	submitted	for	examination	
	
Paper	1	
	
“OBJECTIVE:	
This	 study	 aimed	 to	 determine	 the	 health	 impact	 and	 cost-effectiveness	 of	 introducing	 a	
human	papillomavirus	(HPV)	vaccination	programme	with	a	quadrivalent	vaccine	alongside	
the	existing	 cervical	 cancer	 screening	programme	 in	 comparison	 to	 the	current	 context	 in	
Italy.	
METHODS:	
A	 US	Markov	model	 was	 adapted	 to	 the	 Italian	 context,	 assuming	 under	 base	 case	 80%	
vaccine	coverage	rate,	lifetime	duration	of	protection	in	a	cohort	of	girls	aged	12	years	and	
discount	 rates	 of	 1.5%	and	3%	 for	 health	 benefits	 and	 costs,	 respectively,	 and	 estimating	
direct	medical	costs.	
RESULTS:	
The	 HPV	 vaccination	 in	 association	 with	 the	 current	 screening	 programme	 would	 allow	
avoiding	 1432	 cases	 of	 cervical	 cancer	 (-63.3%)	 and	 513	 deaths	 (-63.4%)	 compared	 to	
screening	 only,	 with	 an	 incremental	 cost-effectiveness	 ratio	 (ICER)	 of	 9569	 euros	 per	
additional	quality-adjusted-life-year	(QALY)	gained.	The	sensitivity	analysis	highlighted	that	
this	model	was	robust	to	all	parameters	presenting	uncertainties	as	the	ICERs	ranged	from	
2,781	euros	to	48,122	euros	per	QALY	gained.	
CONCLUSION:	
This	study	showed	that	HPV	vaccination	in	adolescent	girls	would	be	a	beneficial	and	cost-
effective	public	health	programme	in	Italy”.	
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Paper	2	
	
“BACKGROUND:	
The	economic	evaluation	of	any	human	papillomavirus	(HPV)	vaccination	strategy	requires	
the	measurement	 of	 clinical	 benefits	 (quality-adjusted	 life-years	 [QALY])	 gained	 to	 reflect	
both	the	increase	in	life	expectancy	and	the	economic	benefits	associated	with	an	effective	
intervention.	
OBJECTIVE:	
The	purpose	of	this	pilot	study	was	to	investigate	the	feasibility	of	a	standardized	time	trade-
off	 (TTO)	 procedure	 to	 quantify	 utility	 loss	 in	 health	 states	 affected	 by	 HPV-induced	
pathologies	in	Italy.	
METHODS:	
This	multicenter,	 retrospective,	 observational,	 cross-sectional	 study	was	 designed	 to	 elicit	
data	on	utilities	in	a	cohort	of	women	with	a	histologically	confirmed	diagnosis	of	high-grade	
cervical	intraepithelial	neoplasias	(CIN2-3).	An	algorithm	for	the	computerized	administration	
of	 a	 TTO	 questionnaire	 was	 developed	 for	 the	 standardized	 elicitation	 of	 data	 on	 health	
utilities	in	CIN2-3,	anogenital	warts,	and	invasive	cervical	cancer.	The	European	Quality	of	Life-
5	Dimensions	(EQ-5D)	questionnaire	was	used	to	assess	the	respondents'	baseline	perception	
of	their	health	conditions.	The	correlation	between	utilities	and	age,	time	from	conization	to	
questionnaire	 administration,	 and	 EQ-5D	 score,	 was	 tested	 using	 the	 Spearman	 rank	
correlation	coefficient	(ρ)	as	a	measure	of	validity.	
RESULTS:	
Of	42	enrolled	patients,	36	responded	(85.7%)	(mean	[SD]	age,	37.2	[9.0]	years).	The	women's	
perception	of	 their	health	state	was	high	 (mean	 [SD]	EQ-5D	score,	0.93	 [0.10]).	The	mean	
utility	values	were	0.73	(0.22),	0.71	(0.35),	and	0.02	(0.08)	for	CIN2-3,	anogenital	warts,	and	
invasive	 cervical	 cancer,	 respectively.	 Based	 on	 ρ	 values,	 none	 of	 the	 3	 HPV-induced	
pathologies	considered	was	significantly	correlated	with	utility.	Nonsignificant	variability	was	
found	among	utilities	 elicited	 for	 anogenital	warts	 (range,	 0.54	 [0.47]	 to	 0.79	 [0.27]);	 this	
variability	was	a	limitation	of	this	pilot	study	and	was	likely	the	result	of	the	limited	sample	
size.	
CONCLUSIONS:	
Based	on	the	findings	from	this	pilot	study,	a	TTO	standardized	procedure	is	expected	to	be	
feasible	and	appropriate	for	assessing	utilities	 in	patients	affected	by	HPV-related	diseases	
and	for	cost-effectiveness	analyses	of	cervical	cancer	prevention	in	Italy”.	 	
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Paper	3	
	
“OBJECTIVES:	
The	GIOVE	Study	was	aimed	at	 the	achievement	of	 the	allocative	efficiency	of	 the	budget	
allocated	 to	 the	 prevention	 of	 human	 papillomavirus	 (HPV)-induced	 diseases.	 An	 ex-ante	
determination	 of	 the	 most	 efficient	 allocation	 of	 resources	 between	 screening	 and	
multicohort	quadrivalent	immunisation	programmes	was	followed	by	the	ex-post	assessment	
of	the	allocative	efficiency	achieved	after	a	12-month	period.	
DESIGN:	
A	bound	optimisation	model	was	developed	to	determine	the	ex-ante	allocative	efficiency	of	
resources.	 The	 alternatives	 compared	 were	 the	 screening	 programme	 alone	 and	 the	
quadrivalent	immunisation	with	access	to	screening.	A	sensitivity	analysis	was	carried	out	to	
assess	the	uncertainty	associated	with	the	main	inputs	of	the	model.	Subsequently,	a	cohort	
of	 girls	 with	 a	 complete	 recorded	 vaccination	 history	 was	 enrolled	 in	 an	 observational	
retrospective	study	for	18	months	to	ensure	full	compliance	with	the	recommended	schedule	
of	vaccination	(0,	2,	six	months)	within	a	12-month	time	horizon.	
SETTING:	
Basilicata	region,	in	the	south	of	Italy.	
PARTICIPANTS:	
12 848	girls	aged	12,	15,	18	or	25	years.	
INTERVENTION:	
Immunisation	with	quadrivalent	anti-HPV	vaccine.	
OUTCOME	MEASURES:	
The	vaccination	coverage	rate	was	considered	to	be	the	indicator	of	the	best	possible	benefit,	
given	the	budgetary	constraints.	
RESULTS:	
Assuming	a	vaccine	price	of	€100	per	dose,	a	vaccination	coverage	rate	of	59.6%	was	required	
for	the	most	effective	allocation	of	resources.	The	optimal	rate	of	coverage	was	 initially	 in	
favor	of	the	multicohort	strategy	of	vaccination	against	HPV	(72.8%±2%).	When	the	price	paid	
for	 the	 quadrivalent	 vaccine	 dropped	 to	 €85	 per	 dose,	 the	 most	 efficient	 coverage	 rate	
(69.5%)	shifted	closer	to	the	immunisation	rate	achieved	during	the	12-month	observation	
period.	
CONCLUSIONS:	
The	 bound	 optimisation	 model	 demonstrated	 to	 be	 a	 useful	 approach	 to	 the	 ex-ante	
allocation	and	the	ex-post	assessment	of	the	economic	resources	allocated	to	a	multicohort	
quadrivalent	anti-HPV	vaccination	programme”.	
40	
	
Paper	4	
	
“BACKGROUND:	
Human	papillomavirus	(HPV)	is	the	main	causative	agent	of	benign	and	malign	neoplasms	in	
both	sexes.	The	Italian	recommendations	for	HPV	vaccines	consider	only	females.	The	BEST	II	
study	 (Bayesian	modelling	 to	assess	 the	Effectiveness	of	a	vaccination	Strategy	 to	prevent	
HPV-related	 diseases)	 evaluates	 1)	 the	 cost-effectiveness	 of	 immunization	 strategies	
targeting	 universal	 vaccination	 compared	 with	 cervical	 cancer	 screening	 and	 female-only	
vaccination	and	2)	the	economic	impact	of	immunization	on	various	HPV-induced	diseases.	
OBJECTIVE:	
The	study	aimed	to	evaluate	whether	selective	or	universal	vaccination	was	the	most	cost-
effective	intervention	against	HPV.	
METHODS:	
We	 present	 a	 dynamic	 Bayesian	 Markov	 model	 to	 investigate	 transmission	 dynamics	 in	
cohorts	of	 females	and	males	within	a	55-year	 timeframe.	We	assumed	 that	quadrivalent	
vaccination	(against	HPV	16,	18,	6,	and	11)	is	available	for	12-year-old	individuals.	The	model	
simulates	 the	 progression	 of	 infected	 subjects	 across	HPV-induced	 health	 states	 (cervical,	
vaginal,	vulvar,	anal,	penile,	and	head/neck	cancer	and	anogenital	warts).	The	sexual	mixing	
is	modeled	by	age-,	sex-,	and	sexual	behavioral-specific	matrices	to	obtain	the	dynamic	force	
of	infection.	
RESULTS:	
In	comparison	to	cervical	cancer	screening,	universal	vaccination	results	 in	an	 incremental	
cost-effectiveness	ratio	of	€1,500.	When	universal	 immunization	is	compared	with	female-
only	vaccination,	it	is	cost-effective	with	an	incremental	cost-effectiveness	ratio	of	€11,600.	
Probabilistic	 sensitivity	analysis	 shows	a	 relatively	 large	amount	of	parameter	uncertainty,	
which	interestingly	has,	however,	no	substantial	impact	on	the	decision-making	process.	The	
intervention	 being	 assessed	 seems	 to	 be	 associated	 with	 an	 attractive	 cost-effectiveness	
profile.	
CONCLUSIONS:	
Universal	HPV	vaccination	 is	 a	 cost-effective	 strategy	when	 compared	with	either	 cervical	
cancer	screening	or	female-only	vaccination	within	the	Italian	context”.	
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Paper	5	
	
Abstract:	
“In	2014,	the	Food	and	Drug	Administration	approved	a	new	human	papillomavirus	9-valent	
vaccine	 (9vHPV),	 targeting	 nine	 HPV	 types:	 HPV	 types	 6,	 11,	 16,	 and	 18,	 which	 are	 also	
targeted	by	the	quadrivalent	HPV	vaccine	(4vHPV),	plus	five	additional	high	cancer	risk	HPV	
types	(HPV	types	31,	33,	45,	52,	and	58).	The	current	study	aimed	to	retrieve	systematically,	
qualitatively	and	quantitatively	pool,	as	well	as	critically	appraise	all	available	evidence	on	
9vHPV	from	randomized	controlled	trials	(RCTs).	We	conducted	a	systematic	review	of	the	
literature	on	9vHPV	efficacy,	 immunogenicity	and	safety,	as	well	as	a	systematic	search	of	
registered,	 completed,	 and	 ongoing	 RCTs.	 We	 retrieved	 and	 screened	 227	 records	 for	
eligibility.	A	total	of	10	publications	reported	on	RCTs'	results	on	9vHPV	and	were	included	in	
the	review.	Sixteen	RCTs	on	9vHPV	have	been	registered	on	RCT	registries.	There	is	evidence	
that	9vHPV	generated	a	 response	 to	HPV	 types	6,	 11,	 16	and	18	 that	was	non-inferior	 to	
4vHPV	vaccine.	Vaccine	efficacy	against	five	additional	HPV	type-related	diseases	was	directly	
assessed	on	females	aged	16-26	years	(risk	reduction	against	high-grade	cervical,	vulvar	or	
vaginal	disease	=	96·7%,	95%	CI	80·9%-99·8%).	Bridging	efficacy	was	demonstrated	for	males	
and	females	aged	9-15	years	and	males	aged	16-26	years	(the	lower	bound	of	the	95%	CIs	of	
both	the	geometric	mean	titer	ratio	and	the	difference	in	seroconversion	rates	meeting	the	
criteria	for	non-inferiority	for	all	HPV	types).	Overall,	9vHPV	has	been	proved	to	be	safe	and	
well	tolerated.	Other	RCTs	addressed:	9vHPV	co-administration	with	other	vaccines,	9vHPV	
administration	 in	 subjects	 that	previously	 received	4vHPV	and	9vHPV	efficacy	 in	 regimens	
containing	fewer	than	three	doses.	The	inclusion	of	additional	HPV	types	in	9vHPV	offers	great	
potential	 to	 expand	 protection	 against	 HPV	 infection.	 However,	 the	 impact	 of	 9vHPV	 on	
reducing	 the	global	burden	of	HPV-related	disease	will	 greatly	depend	on	vaccine	uptake,	
coverage,	availability,	and	affordability”.	
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